Arbutus vs. Moderna Patent Case Heads to Jury Trial
Arbutus Biopharma stock rises 5% as judge orders jury trial in patent dispute over mRNA vaccine technology with Moderna, with trial set for March.
/ 2 items
Arbutus Biopharma stock rises 5% as judge orders jury trial in patent dispute over mRNA vaccine technology with Moderna, with trial set for March.
Arbutus Biopharma shares dropped 16% after losing European patent dispute with Moderna. The biotech plans to appeal the ruling that affects ongoing litigation.